中期報告 目錄 公司資料 2 管理層討論及分析 3 其他資料 24 獨立審閱報告 28 中期簡明合併損益及其他全面收益表 29 中期簡明合併財務狀況表 30 中期簡明合併權益變動表 32 中期簡明合併現金流量表 33 中期簡明合併財務資料附註 34 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 中 國 中 藥 控 股 有 限 公 司 （於香港註冊成立之有限公司） （股份代號：570） 截至2023年6月30日止六個月 中期業績公告 及 非執行董事辭任 中國中藥控股有限公司（「本公司」）董事會（「董事會」）欣然呈列本公司及其附屬公司（統稱 為「本集團」）截至2023年6月30日止六個月（「報告期」、「本期」）之未經審核合併業績如下： 業績摘要 截至6月30日止期間 2023年 2022年 變動 人民幣千元人民幣千元 ...

Financial Performance - The company's revenue for 2022 was RMB 14,304,242 thousand, reflecting a compound annual growth rate (CAGR) of 6.17% from 2018 to 2022[4] - Gross profit for 2022 was RMB 7,198,452 thousand, with a gross margin of 50.32%[4] - The operating profit for 2022 decreased to RMB 1,064,283 thousand, representing a decline of 16.18% compared to the previous year[4] - Profit attributable to equity holders for 2022 was RMB 764,266 thousand, down 14.63% year-on-year[4] - The company's net profit margin for 2022 was 5.04%, a decline from previous years[4] - In 2022, the company's revenue was RMB 14.304 billion, a decrease of 24.9% compared to RMB 19.053 billion in 2021[7] - The company's revenue in the second half of 2022 increased by 42.0% compared to the first half, indicating a significant reduction in the downward trend[7] - The company reported a net profit of approximately RMB 720,752,000, a significant decline of 66.1% from RMB 2,123,424,000 in the previous year, with a net profit margin of 5.0% compared to 11.1%[61] - Basic earnings per share decreased by 60.4% to RMB 0.1518 from RMB 0.3838, attributed to a 60.5% drop in profit attributable to equity holders[61] Assets and Liabilities - Total assets as of 2022 amounted to RMB 35,619,941 thousand, showing a steady increase over the five-year period[4] - The company's total liabilities for 2022 were RMB 12,673,339 thousand, indicating a slight decrease from previous years[4] - Current assets totaled approximately RMB 17,966,676,000, a slight decrease from RMB 18,203,046,000[63] - The company's current liabilities increased to approximately RMB 10,102,784,000 from RMB 8,764,528,000, primarily due to the reclassification of medium-term notes[63] - The total equity attributable to owners of the parent company was RMB 20,166,720 thousand in 2022, an increase of 2.3% from RMB 19,718,669 thousand in 2021[173] Cash Flow and Investments - Cash and cash equivalents at the end of 2022 were RMB 3,065,054 thousand, reflecting a decrease from RMB 2,894,757 thousand in 2021[4] - The company’s cash flow from operating activities for 2022 was RMB 1,092,362,000, an increase of 37.2% compared to RMB 796,029,000 in 2021[175] - The company reported a net cash flow from investing activities of RMB (374,153,000) in 2022, an improvement from RMB (536,936,000) in 2021[176] - The company raised RMB 3,000,000,000 from the issuance of unsecured notes in 2022, compared to RMB 1,000,000,000 in 2021[176] Research and Development - The company invested approximately RMB 612 million in research and development, accounting for 4.3% of the revenue during the reporting period, exceeding the industry average[26] - The R&D team consists of 1,309 members, including 3 experts receiving special government allowances and 1 national-level technology innovation leader[27] - The group completed research on 64 national drug standards for traditional Chinese medicine formula granules during the reporting period, totaling 424 standards completed cumulatively, ranking first in the country[27] - The company is focusing on enhancing its technological innovation capabilities, particularly in the areas of TCM raw material resources and national drug standards for TCM formula granules[15] Market Strategy and Expansion - The company plans to focus on market expansion and new product development in the upcoming fiscal year[5] - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[5] - The company aims to leverage its advantages in the entire traditional Chinese medicine industry chain to enhance its market position and drive recovery in 2023[8] - The company is committed to sustainable development and improving healthcare accessibility for the public, actively participating in pandemic response efforts[9] Corporate Governance - The company has completed the main tasks of the three-year action plan for state-owned enterprise reform, enhancing corporate governance and operational efficiency[16] - The board consists of 12 members, including 3 executive directors, 5 non-executive directors, and 4 independent non-executive directors[109] - The independent non-executive directors have confirmed their independence according to the listing rules, ensuring compliance with governance standards[109] - The board is committed to continuously reviewing and improving corporate governance practices to safeguard shareholder interests[108] Social Responsibility and ESG - The group has been recognized with multiple ESG awards, including being listed in the "Top 20 ESG Pharmaceutical Companies" and receiving the "Public Welfare Pioneer" award[30] - The group is committed to social responsibility by integrating TCM material base construction with rural revitalization strategies[33] - The group emphasizes environmental management and has implemented monitoring systems for emissions, including quarterly wastewater monitoring and semi-annual boiler emissions monitoring[129] Compliance and Risk Management - The company is enhancing its compliance governance and has established a compliance responsibility list for key positions to strengthen its operational compliance framework[35] - The company has implemented a mechanism to ensure independent views and opinions from directors are communicated to the board[109] - The board has adopted a risk management and internal control system, which is reviewed at least annually to ensure adequate resources and training for financial reporting[138] Shareholder Information - The board proposed a final dividend of RMB 0.0455 per share for the year ended December 31, 2022, down from RMB 0.0598 per share in 2021[68] - The total amount of dividends distributed for the year ended December 31, 2022, was RMB 0.0455 per share, compared to RMB 0.1152 per share in 2021[71] - The company has adopted a dividend policy aimed at providing reasonable and sustainable returns to shareholders while maintaining financial stability[72] Supply Chain and Procurement - The company has a close relationship with Ping An Group, which holds 12% of its issued share capital[87] - The total procurement agreement with China National Pharmaceutical Group allows for stable and quality raw material procurement[88] - The new procurement agreement sets annual limits of RMB 300,000,000, RMB 450,000,000, and RMB 675,000,000 for the years 2023, 2024, and 2025 respectively[90] Leadership and Management - The company appointed Mr. Chen Yinglong as Chairman of the Board on May 12, 2022, and he has extensive experience in management and pharmaceutical industries[147] - The company has a strong leadership team with members holding various professional qualifications, including senior engineer and chief Chinese medicine practitioner[150] - The management team emphasizes the importance of compliance and quality control in its operations to maintain industry standards[151]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而 產生或因依賴該等內容而引致之任何損失承擔任何責任。 CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 中 國 中 藥 控 股 有 限 公 司 （於香港註冊成立之有限公司） （股份代號：570） 截至2022年12月31日止年度 全年業績公佈 中國中藥控股有限公司（「本公司」或「公司」）董事（「董事」）會（「董事會」）欣然呈列本公司 及其附屬公司（統稱為「本集團」）截至2022年12月31日止年度（「報告期」或「本期」）之合併 業績： 業績摘要 截至12月31日止年度 2022年 2021年 變動 人民幣千元 人民幣千元 ...